Cargando…

Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment

INTRODUCTION: Fractures caused by osteoporosis are prevalent among elderly females, which reduce quality of life significantly. This study aimed at comparing cost-effectiveness of Zoledronic acid in preventing and treating post-menopause osteoporosis as compared with routine medical treatment. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golmohamdi, Fateme Rostami, Abbasi, Mahnaz, Karyani, Ali Kazemi, Sari, Ali Akbari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Electronic physician 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279979/ https://www.ncbi.nlm.nih.gov/pubmed/28163861 http://dx.doi.org/10.19082/3434

Ejemplares similares

The Economic Burden of Liver Cirrhosis in Iran: a Cost of Illness Study
por: AKBARI SARI, Ali, et al.
Publicado: (2015)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women
por: Chao, Ma, et al.
Publicado: (2013)

Eliciting Preferences for Health Insurance in Iran Using Discrete Choice Experiment Analysis
por: Kazemi Karyani, Ali, et al.
Publicado: (2019)

Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
por: Carmona, Raj, et al.
Publicado: (2009)

Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis
por: Gazoni, Fernanda Martins, et al.
Publicado: (2023)

Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel, Agnès, et al.
Publicado: (2011)

Zoledronic acid infusion for prevention and treatment of osteoporosis
por: Sunyecz, John A
Publicado: (2010)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

IDUA Gene Variants and Response to Zoledronic Acid Treatment in Chinese Women with Postmenopausal Osteoporosis
por: Lin, Haiqing, et al.
Publicado: (2021)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study
por: Spangler, Leslie, et al.
Publicado: (2023)

Self-reported health-related quality of life (HRQoL) and factors affecting HRQoL among individuals with health insurance in Iran
por: Karyani, Ali Kazemi, et al.
Publicado: (2016)

Developing attributes and levels for a discrete choice experiment on basic health insurance in Iran
por: Kazemi Karyani, Ali, et al.
Publicado: (2018)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Zoledronic acid does not slow spinal radiographic progression of osteoarthritis in postmenopausal women with osteoporosis and radiographic osteoarthritis
por: Host, L.V., et al.
Publicado: (2022)

Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
por: Kang, Taewook, et al.
Publicado: (2022)

Bazedoxifene for the prevention of postmenopausal osteoporosis
por: Gennari, Luigi, et al.
Publicado: (2008)

Application of discrete choice experiments to estimate value of life: a national study protocol in Iran
por: Mirzaee, Negar, et al.
Publicado: (2021)

The Combination Therapy with Zoledronic Acid and Propranolol Improves the Trabecular Microarchitecture and Mechanical Property in an Rat Model of Postmenopausal Osteoporosis
por: Khajuria, Deepak Kumar, et al.
Publicado: (2014)

The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: A clinical trial study
por: Gokosmanoglu, Feyzi, et al.
Publicado: (2016)

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2020)

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
por: Lambrinoudaki, Irene, et al.
Publicado: (2008)

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2009)

Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA
por: Ito, Kouta
Publicado: (2018)

Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
por: Moriwaki, K., et al.
Publicado: (2017)

Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
por: Bellone, Federica, et al.
Publicado: (2021)

Effect of Zoledronic Acid on the Vertebral Body Bone Mineral Density After Instrumented Intervertebral Fusion in Postmenopausal Women With Osteoporosis
por: Fan, Junjun, et al.
Publicado: (2021)

Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment
por: Boran, Gökçen, et al.
Publicado: (2020)

The Potential Mechanism of Exercise Combined with Natural Extracts to Prevent and Treat Postmenopausal Osteoporosis
por: Zhou, Tongxi, et al.
Publicado: (2021)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Hormone replacement therapy and the prevention of postmenopausal osteoporosis
por: Gambacciani, Marco, et al.
Publicado: (2014)

Therapeutic Options in the Prevention and Treatment of Postmenopausal Osteoporosis
por: Kamel, Hosam K., et al.
Publicado: (2006)

Postmenopausal Osteoporosis
por: Kamel, Hosem K.
Publicado: (2006)

Management of osteoporosis in the aging male: Focus on zoledronic acid
por: Piper, Paul K, et al.
Publicado: (2009)

Six monthly intravenous zoledronic acid in childhood osteoporosis
por: Munns, CF, et al.
Publicado: (2013)

Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis
por: Kong, Li, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4rvc8i88b0govsa5bsdq48be1l